Indivior PLC
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IZQVF research report →
About the company
Indivior PLC, along with its various associated companies, focuses on the creation, production, and distribution of buprenorphine-derived prescription pharmaceuticals. These medications are primarily utilized in the management of opioid addiction and concurrent mental health disorders. The firm's ongoing product development initiatives are geared towards advancing therapies for opioid use disorder, other forms of addiction, and schizophrenia.
- CEO
- Mark Crossley
- IPO
- 2014
- Employees
- 1,000
- HQ
- North Chesterfield, VA, US
Price Chart
- Market Cap
- $2.89B
- P/E
- 19.80
- P/S
- 3.85
- P/B
- -34.65
- EV/EBITDA
- 15.06
- Div Yield
- 0.00%
- Gross Margin
- 83.11%
- Op Margin
- 33.31%
- Net Margin
- 19.44%
- ROE
- -142.01%
- ROIC
- 85.68%
- 52W High
- $26.50
- 52W Low
- $15.00
- 50D MA
- $18.99
- 200D MA
- $19.42
- Beta
- -0.06
- Avg Volume
- 3.59K
Get TickerSpark's AI analysis on IZQVF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our IZQVF coverage
Recent articles, reports, and earnings notes.
No research on IZQVF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IZQVF report →Similar companies
Peers in the same neighborhood.